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Unsymmetrically substituted imidazolium salts were synthesized and characterized using 1H-NMR and 
13C-NMR. The antimicrobial activities of the salts were evaluated using the agar-well diffusion method 
against 14 bacteria and five yeasts. The minimal inhibitory concentrations (MIC) against seven bacteria 
and one yeast were also determined. Among the test compounds applied, 1, 2, 3, 6 and 11 showed 
activities against Micrococcus luteus ATCC 9341, Staphylococcus aureus ATCC 25923, Staphylococcus 
epidermidis ATCC 12228, Bacilllus cereus ATCC 11778, Bacillus subtilis ATCC 6633, Bacillus 
thuringiensis, Listeria monocytogenes ATCC 19112 and Candida trophicalis. However, compounds 1, 2 
and 3 showed the highest antimicrobial activities against Micrococcus luteus ATCC 9341, Stapylococcus 
aureus ATCC 25923, Staphylococcus epidermidis ATCC 12228, Bacilllus cereus ATCC 11778 and 
Bacillus subtilis ATCC 6633 with inhibition zones of 14-20 mm. In addition, compound 6 have only 
demonstrated activities against Candida trophicalis while compounds 4, 5, 7, 8, 9, 10, 12, 13 and 14 
had no effect on test microorganisms.
Uniterms: Imidazolium salts/characterization. N-heterocyclic carbenes. Imidazolium salts/antimicrobial 
activity. Imidazolium salts/Minimum inhibitory concentration.
INTRODUCTION
Imidazolium salts (IMSs) are best known for their 
applications in organic synthesis at room-temperature 
ionic liquids, or as precursors of stable carbenes, but 
they also show important biological properties such 
as antimicrobial activity. A large variety of these salts 
have been used as anti-inflammatory, antibacterial, 
antifungal and thromboxane synthetase enzyme inhibitor 
(Dominianni, Yen, 1989; Odzˇak, Skocˇıbušıc´, Maravıc´, 
2013; Riduan, Zhang, 2013; Elshaarawy et al., 2014; 
Reinhardt et al., 2014).
Imidazole derived NHC precursors are known 
in the field of organometallic chemistry for more than 
five decades and the imidazole ring presents a structural 
fragment that plays an important role in many biological 
systems such as enzymes, metallo-proteins as well as in 
natural products and anticancer drugs (Jaouen, 2006). It 
also serves as a good ligand in various transition metal 
complexes (Navarro, Lippert, 2001).
Several  si tes around IMS are amenable to 
modification: (i) the nitrogen substituents (1 and 12) 
and (ii) the backbone carbon substituents (2 and 13). 
IMSs were prepared with different alkyl and aryl groups 
to establish the contributions of the type and size of 
the substituents to the activity. The introduction of 
sterically hindered groups to the nitrogen atoms that 
are the part of aromatic rings were believed to influence 
the activity.
One of the first instances of the use of IMSs as an 
antimicrobial agent was reported by Demberelnymba et al. 
(2004), in which a series of N-alkyl-N-methylimidazolium 
halides, and N-alkyl-N-hydroxyethylimidazolium 
chlorides were found to possess low MIC values against 
a range of microbes. They stated that the antibacterial and 
fungicidal activities were greatly affected by their chain 
length, the type of substituted functional groups, and their 
position in the imidazolium ring. 
Based on these studies, we have discussed the 
synthesis and characterization of unsymmetrically 
substituted imidazolium salts and evaluated their 
antimicrobial properties.
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MATERIAL AND METHODS
Material and measurements
1H- and 13C-NMR measurements were performed 
using a Varian Mercury 400 spectrometer operating at 
400 and 100 MHz, respectively. NMR multiplicities are 
abbreviated as follows: s, singlet; d, doublet; t, triplet; m, 
multiplet signal. Coupling constants J are given in Hz. 
Melting points were measured in open capillary tubes with 
a Stuart-SMP30 melting point apparatus.
Synthesis of 1-5
A solution of N-(2,4,6-trimethylphenyl) imidazole 
(2.0 mmol) (Zeng et al., 2010) in toluene (10.0 mL) was 
added slowly to 2,4,6-trimethylbenzyl bromide/2,4,5,6-
tetramethylbenzyl bromide/2,3,4,5,6-pentamethylbenzyl 
bromide (Van der  Made,  Van der  Made,  1993) 
/1-bromoethanole/2-chloroethylamine hydrochloride 
(2.0 mmol) at 110 °C for 18 h. Diethylether (15.0 mL) 
was added to obtain a white crystalline solid which was 
filtered off. The solid was washed with Et2O (3×15.0 
mL), and dried under vacuum. The crude product was 
recrystallized from CH2Cl2/Et2O (Compound for 1-3 
Günay, Çoğaşlıoğlu, Fırıncı (2015), compound 4,5 for 
Gençay (2013)).
Compound 1: N-(2,4,6-trimethylphenyl)-N’-(2,4,6-
trimethylbenzyl)imidazolium bromide 
Yield: % 80. m.p.: 273-275 oC. 1H-NMR (δ, 400 
MHz, CDCl3): 1.96 [s, 6H, C6H2(CH3)3-o-CH3]; 2.03 
[s, 6H, C6H2(CH3)3-o-CH3]; 2.25 [s, 3H, C6H2(CH3)3-
p-CH3]; 2.29 [s, 3H, C6H2(CH3)3-p-CH3]; 5.92 [s, 2H, 
NCH2C6H2(CH3)3]; 6.89 [s, 1H, NCHCHN]; 6.94 [s, 1H, 
NCHCHN]; 7.17 [d, 2H, NCH2C6H2(CH3)3]; 7.21 [s, 2H, 
NC6H2(CH3)3]; 10.39 [s, 1H, NCHN]. 13C-NMR (δ, 100 
MHz, CDCl3): 17.6 [C6H2(CH3)3]; 19.9 [C6H2(CH3)3]; 
21.0  [CH 2C 6H 2(CH 3) 3] ;  21.0  [CH 2C 6H 2(CH 3) 3] ; 
48.6 [NCH2C6H2(CH3)3]; 121.7 [NCHCHN]; 123.6 
[NCHCHN]; 125.7 [C6H2(CH3)3]; 129.8 [C6H2(CH3)3]; 
129.9 [C 6H 2(CH 3) 3] ;  130.6 [C 6H 2(CH 3) 3] ;  134.1 
[CH2C6H2(CH3)3]; 137.3 [CH2C6H2(CH3)3]; 138.1 
[CH2C6H2(CH3)3]; 139.9 [CH2C6H2(CH3)3]; 141.2 
[NCHN].
Compound 2: N-(2,4,6-trimethylphenyl)-N’-(2,3,5,6-
tetramethylbenzyl)imidazolium bromide
Yield: % 80. m.p.: 280-283 oC. 1H-NMR (δ, 400 
MHz, CDCl3): 2.01 [s, 6H, C6H2(CH3)3-o-CH3]; 2.18 
[s, 6H, C6H(CH3)4-o-CH3]; 2.23 [s, 6H, C6H(CH3)4-
m-CH3]; 2.26 [s, 6H, C6H2(CH3)3-p-CH3]; 5.95 [s, 2H, 
NCH2C6H(CH3)4]; 6.91 [t, 1H, NCHCHN]; 6.99 [t, 1H, 
NCHCHN]; 7.15 [s, 2H, NC6H2(CH3)3]; 7.27 [s, 1H, 
C6H(CH3)4]; 10.29 [s, 1H, NCHN]. 13C-NMR (δ, 100 
MHz, CDCl3): 15.8 [C6H2(CH3)3]; 17.6 [C6H2(CH3)3]; 20.4 
[C6H(CH3)4]; 21.0 [C6H(CH3)4]; 49.1 [NCH2C6(CH3)5]; 
121.8 [NCHCHN]; 123.7 [NCHCHN]; 128.4 [C6H(CH3)4]; 
129 .8  [C 6H(CH 3) 4] ;  130 .6  [C 6H(CH 3) 4] ;  133 .4 
[C6H(CH3)4]; 134.0 [C6H2(CH3)3]; 134.1 [C6H2(CH3)3]; 
134.9 [C6H2(CH3)3]; 137.2 [C6H2(CH3)3]; 141.2 [NCHN].
Compound 3: N-(2,4,6-trimethylphenyl)-N’-(2,3,4,5,6-
pentamethylbenzyl)imidazolium bromide
Yield: % 85. m.p.: 290-293 oC. 1H-NMR (δ, 400 
MHz, CDCl3): 2.07 [s, 6H, C6H2(CH3)3-o-CH3]; 2.23 [s, 6H, 
C6(CH3)5-o-CH3]; 2.26 [s, 3H, C6H2(CH3)3-p-CH3]; 2.28 [s, 
6H, C6(CH3)5-m-CH3]; 2.32 [s, 3H, C6(CH3)5-p-CH3]; 6.01 
[s, 2H, NCH2C6(CH3)5]; 6.98 [s, 1H, NCHCHN]; 7.26 [s, 
1H, NCHCHN]; 10.32 [s, 1H, NCHN]. 13C-NMR (δ, 100 
MHz, CDCl3): 16.7 [C6H2(CH3)3-o-CH3]; 16.9 [C6(CH3)5-
o-CH3]; 17.2 [C6(CH3)5-m-CH3]; 17.6 [C6H2(CH3)3-p-
CH3]; 21.0 [C6(CH3)5-p-CH3]; 49.8 [NCH2C6(CH3)5]; 121.9 
[NCHCHN]; 123.4 [NCHCHN]; 125.7 [C6(CH3)5]; 129.8 
[C6(CH3)5]; 130.6 [C6(CH3)5]; 133.5 [C6(CH3)5]; 133.7 
[C6H2(CH3)3]; 134.1 [C6H2(CH3)3]; 137.1 [C6H2(CH3)3]; 
137.2 [C6H2(CH3)3]; 141.2 [NCHN].
Compound 4: N-(2,4,6-trimethylphenyl)-N’-
(hydroxyethyl)imidazolium bromide
Yield: 85%. m.p.: 163-165 oC.1H-NMR (δ, 400 
MHz, DMSO): 2.01 [s, 6H, C6H2(CH3)3-o-CH3]; 2.31 
[s, 3H, C6H2(CH3)3-p-CH3]; 3.81 [t, J = 5.0 Hz, 2H, 
NCH2CH2OH]; 4.36 [t, J = 5.0 Hz, 2H, NCH2CH2OH]; 7.12 
[s, 2H, C6H2(CH3)3]; 7.91 [s, 1H, NCHCHN]; 8.08 [s, 1H, 
NCHCHN]; 9.47 [s, 1H, NCHN]. 13C-NMR (δ, 100 MHz, 
DMSO): 17.6 [C6H2(CH3)3-o-CH3]; 21.2 [C6H2(CH3)3-p-
CH3]; 52.6 [NCH2CH2OH]; 59.7 [NCH2CH2OH]; 124.1 
[NCHCHN]; 124.4 [NCHCHN]; 129.9 [C6H2(CH3)3]; 
131.9 [C 6H 2(CH 3) 3] ;  135.0 [C 6H 2(CH 3) 3] ;  138.4 
[C6H2(CH3)3]; 140.9 [NCHN].
Compound 5: N-(2,4,6-trimethylphenyl)-N’-
(ethylamine)imidazolium chloride hydrochloride
Yield: 80%. m.p.: 203-205 oC. 1H-NMR (δ , 
400 MHz, DMSO): 2.06 [s, 6H, C6H2(CH3)3-o-CH3]; 
2.29 [s, 3H, C6H2(CH3)3-p-CH3]; 3.86 [t, J = 5.85 Hz, 
2H, NCH2CH2NH2.HCl]; 4.68 [t, J = 5.85 Hz, 2H, 
NCH2CH2NH2.HCl]; 7.09 [s, 2H, C6H2(CH3)3]; 7.93 [s, 
1H, NCHCHN]; 8.24 [s, 1H, NCHCHN]; 8.55 [br, 1H, 
NH2.HCl]; 9.68 [s, 1H, NCHN]. 
13C-NMR (δ, 100 MHz, 
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DMSO): 17.8 [C6H2(CH3)3-o-CH3]; 21.0 [C6H2(CH3)3-p-
CH3]; 38.1 [NCH2CH2NH2.HCl]; 47.3 [NCH2CH2NH2.
HCl]; 123.8 [NCHCHN]; 124.3 [NCHCHN]; 129.7 
[C6H2(CH3)3]; 131.4 [C6H2(CH3)3]; 134.8 [C6H2(CH3)3]; 
138.7 [C6H2(CH3)3]; 140.6 [NCHN].
Synthesis of 6
1-Ferrocenylethanol (1.0 mmol) and N-(2,4,6-
trimethyphenyl)imidazole (1.1 mmol) were dissolved 
in acetic acid (3.0 mL) and stirred at 60 °C for 7 h. After 
removing most of acetic acid, a solution of LiCl (4.0 
mmol) in EtOH (20.0 mL) was added, and stirred for 8 h 
at room temperature. After removing the volatiles, filtered 
through Celite, the crude was purified from CH2Cl2/Et2O 
(Yenisarı, 2014; Seo et al., 2003).
Compound 6: N-(ferrocenylethyl)-N’-(2,4,6-
trimethylphenyl)imidazolium chloride 
Yield: 62%. 1H-NMR (δ, 400 MHz, DMSO): 1.97 
[s, 9H, C6H2(CH3)3-o,p-(CH3)]; 2.30 [s, 3H, FcCHCH3]; 
4.23 [s, 5H, Fc-H]; 4.39 [s, 2H, Fc-H]; 4.44 [s, 2H, Fc-
H]; 5.68-5.82 [m, 1H, FcCHCH3]; 7.11 [d, J = 6.7 Hz, 
2H, C6H2(CH3)3]; 7.92 [s, 1H, NCHCHN]; 8.18 [s, 1H, 
NCHCHN]; 9.87 [s, 1H, NCHN]. 13C-NMR (δ, 100 MHz, 
DMSO): 16.8 [C6H2(CH3)3-o-(CH3)]; 16.9 [C6H2(CH3)3-o-
(CH3)]; 20.2 [C6H2(CH3)3-p-(CH3)]; 21.1 [FcCHCH3]; 55.8 
[FcCHCH3]; 65.9 [Fc-C]; 67.3 [Fc-C]; 68.1 [Fc-C]; 68.6 
[Fc-C]; 68.8 [Fc-C]; 78.8 [Fc-C]; 79.1 [Fc-C];79.4 [Fc-C]; 
87.3 [Fc-C]; 121.4 [NCHCHN]; 123.9 [NCHCHN]; 128.9 
[C6H2(CH3)3]; 131.1 [C6H2(CH3)3]; 134.0 [C6H2(CH3)3]; 
136.3 [C6H2(CH3)3]; 140.0 [NCHN].
Synthesis of 7-9
These compounds were synthesized according to the 
method in the literature (Günay et al., 2009).
Compound 7: N-(methyl)-N’-(2,3,5,6-
tetramethylbenzyl)imidazolium bromide
Yield: 83%, m.p.: 123–125 oC. 1H-NMR (δ, 400 
MHz, CDCl3): 2.16 [s, 6H, C6H(CH3)4-o-CH3]; 2.21 [s, 
6H, C6H(CH3)4-m-CH3]; 4.09 [s, 3H, NCH3]; 5.59 [s, 2H, 
NCH2C6H(CH3)4]; 6.90 [d, 1H, J = 1.6 Hz, NCHCHN]; 
7.01 [s, 1H, C6H(CH3)4]; 7.51 [d, 1H, J = 1.6 Hz, 
NCHCHN]; 10.02 [s, 1H, NCHN]. 13C-NMR (δ, 100 
MHz, CDCl3): 16.1 [C6H(CH3)4-o-CH3]; 20.6 [C6H(CH3)4-
m-CH3]; 37.3 [NCH3]; 48.8 [NCH2C6H(CH3)4]; 121.1 
[NCHCHN]; 123.8 [NCHCHN]; 128.1 [C6H(CH3)4]; 133.8 
[C6H(CH3)4]; 134.3 [C6H(CH3)4]; 135.2 [C6H(CH3)4]; 
137.2 [NCHN].
Compound 8: N-(methyl)-N’-(2,3,4,5,6-
pentamethylbenzyl)imidazolium bromide
Yield: 94%, m.p.: 192–194 oC. 1H-NMR (δ, 400 
MHz, CDCl3): 2.17 [s, 6H, C6(CH3)5-o-CH3]; 2.18 [s, 6H, 
C6(CH3)5-m-CH3]; 2.21 [s, 3H, C6(CH3)5-p-CH3]; 4.08 
[s, 3H, NCH3]; 5.57 [s, 2H, NCH2C6(CH3)5]; 6.91 [d, 
1H, J = 1.6 Hz, NCHCHNCH3]; 7.54 [d, 1H, J = 1.6 Hz, 
NCHCHNCH3]; 9.94 [s, 1H, NCHN]. 13C-NMR (δ, 100 
MHz, CDCl3): 17.0 [C6(CH3)5-o-CH3]; 17.1 [C6(CH3)5-
m-CH3]; 17.4 [C6(CH3)5-p-CH3]; 37.2 [NCH3]; 49.3 
[NCH2C6(CH3)5]; 121.1 [NCHCHN]; 123.9 [NCHCHN]; 
125.4 [C6(CH3)5]; 133.8 [C6(CH3)5]; 133.9 [C6(CH3)5]; 
136.9 [C6(CH3)5]; 137.5 [NCHN].
Compound 9: N-(methyl)-N’-(2-methoxyethyl)
imidazolium chloride
Yield: 72% (air sensitive). 1H-NMR (δ, 400 
MHz, CDCl3): 3.30 [s, 3H, NCH3]; 3.70-3.72 [m, 2H, 
NCH2CH2OCH3]; 4.05 [s, 3H, NCH2CH2OCH3]; 4.52-4.54 
[m, 2H, NCH2CH2OCH3]; 7.57-7.59 [m, 2H, NCHCHN]; 
10.37 [s, 1H, NCHN].
Synthesis of 10-12
These compounds were synthesized according to 
the literature method (Compounds for 10, 11 Günay et 
al. (2009), compound for 12 Günay, Çoğaşlıoğlu (2016)).
Compound 10: N-(butyl)-N’-(2,4,6-trimethylbenzyl)
imidazolium bromide
Yield: 84%. m.p.: 100 oC. 1H-NMR (δ, 400 MHz, 
CDCl3): 0.83 [t, 3H, J = 7.2 Hz, CH3CH2CH2CH2N]; 
1 .26 [m,  2H,  CH 3CH 2CH 2CH 2N];  1 .81 [m,  2H, 
CH3CH2CH2CH2N]; 2.16 [s, 9H, C6H2(CH3)3-o,p-CH3]; 
4.27 [t, 2H, J = 7.2 Hz, CH3CH2CH2CH2N]; 5.49 [s, 
2H, NCH2C6H2(CH3)3]; 6.80 [s, 2H, C6H2(CH3)3]; 6.80 
[s, 2H, NCHCHN]; 7.60 [s, 2H, NCHCHN]; 10.26 
[s, 1H, NCHN]. 13C-NMR (δ, 100 MHz, CDCl3): 
13.4 [CH3CH2CH2CH2N]; 19.4 [CH3CH2CH2CH2N]; 
19.8 [C6H2(CH3)3-o-CH3]; 21.0 [C6H2(CH3)3-p-CH3]; 
32.1 [CH3CH2CH2CH2N]; 47.8 [CH3CH2CH2CH2N]; 
5 0 . 0  [ N C H 2C 6H 2( C H 3) 3] ;  1 2 0 . 6  [ N C H C H N ] ; 
122.3  [NCHCHN];  125.3  [C 6H 2(CH 3) 3] ;  130.0 
[C6H2(CH3)3]; 136.7 [C6H2(CH3)3]; 138.0 [C6H2(CH3)3]; 
139.9 [NCHN].
Compound 11: N-(butyl)-N’-(2,3,5,6-
tetramethylbenzyl)imidazolium bromide
Yield: 81%. m.p.: 110 oC. 1H-NMR (δ, 400 MHz, 
CDCl3): 0.85 [t, 3H, J = 7.4 Hz, CH3CH2CH2CH2N]; 
1 .30 [m,  2H,  CH 3CH 2CH 2CH 2N];  1 .84 [m,  2H, 
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CH3CH2CH2CH2N]; 2.09 [s, 6H, C6H(CH3)4-o-CH3]; 
2.14 [s, 6H, C6H(CH3)4-m-CH3]; 4.29 [t, 2H, J = 7.4 
Hz, CH3CH2CH2CH2N]; 5.57 [s, 2H, NCH2C6H(CH3)4]; 
6.81 [s, 1H, NCHCHN]; 6.95 [s, 1H, C6H(CH3)4]; 7.59 
[s, 1H, NCHCHN]; 10.27 [s, 1H, NCHN]. 13C-NMR 
(δ, 100 MHz, CDCl3): 13.4 [CH3CH2CH2CH2N]; 15.8 
[CH3CH2CH2CH2N]; 19.4 [C6H(CH3)4-o-CH3]; 20.4 
[C6H(CH3)4-p-CH3]; 32.1 [CH3CH2CH2CH2N]; 48.5 
[CH3CH2CH2CH2N]; 50.0 [NCH2C6H(CH3)4]; 120.8 
[NCHCHN]; 122.4 [NCHCHN]; 128.0 [C6H(CH3)4]; 
129 .7  [C 6H(CH 3) 4] ;  133 .4  [C 6H(CH 3) 4] ;  134 .0 
[C6H(CH3)4]; 135.0 [C6H(CH3)4]; 135.8 [NCHN]; 136.4 
[C6H(CH3)4].
Compound 12: N-(butyl)-N’-(2,3,4,5,6-
pentamethylbenzyl)imidazolium bromide
Yield: 89%. m.p.: 117 oC. 1H-NMR (δ, 400 MHz, 
CDCl3): 0.86 [t, 3H, J = 7.4 Hz, CH3CH2CH2CH2N]; 
1 .29 [m,  2H,  CH 3CH 2CH 2CH 2N];  1 .83 [m,  2H, 
CH3CH2CH2CH2N]; 2.13 [s, 6H, C6(CH3)5-o-CH3]; 2.14 
[s, 6H, C6(CH3)5-m-CH3]; 2.17 [s, 3H, C6(CH3)5-p-CH3]; 
4.29 [t, 2H, J = 7.2 Hz, CH3CH2CH2CH2N]; 5.57 [s, 2H, 
NCH2C6(CH3)5]; 6.83 [t, 1H, J = 1.7 Hz, NCHCHN]; 7.54 
[t, 1H, J = 1.7 Hz, NCHCHN]; 10.14 [s, 1H, NCHN]. 
13C-NMR (δ, 100 MHz, CDCl3): 13.4 [CH3CH2CH2CH2N]; 
16.8 [CH3CH2CH2CH2N]; 16.9 [C6(CH3)5-o-CH3]; 
17.2 [C6(CH3)5-m-CH3]; 19.4 [C6(CH3)5-p-CH3]; 32.1 
[CH3CH2CH2CH2N]; 49.0 [CH3CH2CH2CH2N]; 50.0 
[NCH2C6(CH3)5]; 120.8 [NCHCHN]; 122.2 [NCHCHN]; 
125.3 [C6(CH3)5]; 133.5 [C6(CH3)5]; 133.7 [C6(CH3)5]; 
136.4 [C6(CH3)5]; 137.2 [NCHN].
Synthesis of 13, 14
These compounds were synthesized according to the 
literature method (Meyer, Taige, Strassner, 2009).
Compound 13: N-(1-methyl-2-oxopropyl)-N’-(2,3,5,6-
tetramethylbenzyl)imidazolium bromide
Yield: 79%; m.p: 187 0C. 1H-NMR (δ, 400 MHz, 
CDCl3): 1.81 [d, J = 7.4 Hz, 3H, CH3]; 2.10 [s, 6H, 
C6H(CH3)4-o-CH3]; 2.14 [s, 6H, C6H(CH3)4-m-CH3]; 
3.68 [s, 3H, OCH3]; 5.57 [s, 2H, NCH2C6H(CH3)4]; 
5.90 [q, J = 6.9 Hz, 2H, CH]; 6.89 [s, 1H, NCHCHN]; 
6.95 [s, 1H, C6H(CH3)4]; 7.69 [s, 1H, NCHCHN]; 10.27 
[s, 1H, NCHN]. 13C-NMR (δ, 100 MHz, CDCl3): 15.4 
[NCH2C6H(CH3)4]; 17.9 [CH3]; 20.1 [NCH2C6H(CH3)4]; 
48.3 [CH]; 53.2 [NCH2C6H(CH3)4]; 57.2 [OCH3]; 120.2 
[NCHHN]; 121.4 [NCHCHN]; 127.4 [C6H(CH3)4]; 133.2 
[C6H(CH3)4]; 133.7 [C6H(CH3)4]; 134.6 [C6H(CH3)4]; 
136.6 [NCHN]; 168.8 (C=O).
Compound 14: N-(1-methyl-2-oxopropyl)-N’-
(2,3,4,5,6-pentamethylbenzyl)imidazolium bromide
Yield: 82%; m.p.: 193 0C. 1H-NMR (δ, 400 MHz, 
CDCl3): 1.83 [d, J = 7.4 Hz, 3H, CH3]; 2.14 [s, 6H, 
C6(CH3)5-o-CH3]; 2.16 [s, 6H, C6(CH3)5-m-CH3]; 2.18 [s, 
3H, C6(CH3)5-p-CH3]; 3.70 [s, 3H, OCH3]; 5.58 [s, 2H, 
NCH2C6(CH3)5]; 5.94 [q, J = 7.2 Hz, 2H, CH]; 6.90 [s, 1H, 
NCHCHN]; 7.67 [s, 1H, NCHCHN]; 10.30 [s, 1H, NCHN]. 
13C-NMR (δ, 100 MHz, CDCl3): 17.0 [NCH2C6(CH3)5]; 
17.1 [NCH2C6(CH3)5]; 17.4 [NCH2C6(CH3)5]; 18.4 [CH3]; 
49.5 [CH]; 53.7 [NCH2C6(CH3)5]; 57.8 [OCH3]; 120.9 
[NCHHN]; 122.3 [NCHCHN]; 125.4 [C6(CH3)5]; 133.8 
[C6(CH3)5]; 134.0 [C6(CH3)5]; 136.9 [C6(CH3)5]; 137.5 
[NCHN]; 169.4 (C=O).
Antimicrobial assays
Antimicrobial activity was determined using the 
following microorganisms. The Gram-negative (Gr-
) were: Escherichia coli ATCC 35218, Salmonella 
typhimurium ATCC 14028, Proteus vulgaris ATCC 
33420, Serratia marcescens ATCC 13880, Enterobacter 
aerogenes ATCC 13048, and the Gram-positive (Gr+) 
were: Micrococcus luteus ATCC 9341, Staphylococcus 
aureus ATCC 25923, Staphylococcus epidermidis ATCC 
12228, Bacilllus cereus ATCC 11778, Bacilllus subtilis 
ATCC 6633, Bacillus thuringiensis, Enterococcus faecalis 
ATCC 29212, Streptococcus pneumoniae ATCC 27336 
and Listeria monocytogenes ATCC 19112, and the yeasts 
were: Candida albicans ATCC 10231, Candida utilis 
ATCC 9950, Candida tropicalis, Candida glabrata and 
Saccharomyces cerevisiae ATCC 9763. Thirteen bacterial 
strains and three yeast strains were obtained from the 
American Type Culture Collection (ATCC, Rockville, 
MD, USA). Other strains were obtained from Faculty of 
Medicine, Adnan Menderes University.
Screenings for antimicrobial activities were 
carried out by the agar well diffusion method against 
test microorganisms (Collins et al., 2004; Clinical and 
Laboratory Standards Institute, 2015). Fresh stock 
solutions (1000 µg mL-1) of the compounds were prepared 
in DMSO according to the needed concentrations for the 
experiments. The inoculum suspensions of the tested 
bacteria and yeasts were prepared from the broth cultures 
(18–24 h) and the turbidity equivalent adjusted to 0.5 
McFarland standard tubes to give a concentration of 1 x 
108 bacterial cells and 1 x 106 yeast cells/mL. To test the 
antimicrobial activity of each unsymmetrically substituted 
imidazolium salts, Mueller Hinton Agar medium (25 mL) 
was poured into each petri plate and was inoculated with 
0.1 mL broth culture of bacteria or yeasts. Then using 
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sterile cork borer of 6 mm diameter, wells were bored 
into the seeded agar plates and were loaded with a 50 µL 
volume of unsymmetrically substituted imidazolium salts. 
Plates inoculated with E. coli ATCC 35218, S. 
typhimurium ATCC 14028, S. aureus ATCC 25923, S. 
epidermidis ATCC 12228, E. faecalis ATCC 29212, S. 
pneumoniae ATCC 27336, S. marcescens ATCC 13880, 
P. vulgaris ATCC 33420, L. monocytogenes ATCC 19112, 
and E. aerogenes ATCC 13048 were incubated at 37 
oC for 24 h and those inoculated with M. luteus ATCC 
9341, B. cereus ATCC 11778, B. subtilis ATCC 6633, B. 
thuringiensis, C. albicans ATCC 10231, C. utilis ATCC 
9950 C. tropicalis, C. glabrata and S. cerevisiae ATCC 
9763 were incubated at 30 oC for 24 h.
After incubation, the diameter of the inhibition 
zone was measured. Discs of Chloramphenicol (C30, 
Oxoid), Gentamycin (GN10 Oxoid), Tetracycline (TE30), 
Erytromycine (E15), Ampicillin (AMP10) and Nystatine 
(NS100) were used as positive controls. 
The minimum inhibitory concentrations (MIC) 
were determined for antimicrobial activities by 
preparing a microdilution broth (Jones et al., 1985; 
Jorgensen, Ferraro, 2009; CLSI, 2009). All the bacteria 
were inoculated in the Nutrient Broth and incubated 
at 30-37 0C for 24 h while the yeasts were inoculated 
in Malt Extract Broth and incubated at 30 0C for 48 h. 
The compounds were dissolved in DMSO (2 mg mL-1). 
From the stock solution, two fold serial dilutions of the 
compounds were employed to determine the MIC ranging 
from 256 to 0.125 µg mL-1. The lowest concentration of 
antimicrobial agent that resulted in complete inhibition 
of the microorganisms was represented as MIC (µg mL-
1). As positive controls, Streptomycin (I.E. Ulagay) for 
bacteria and Nystatine (NS100, Oxoid) for yeast were 
used in the dilution method.
RESULTS AND DISCUSSION
Imidazole has been easily converted into IMSs by 
attachment of a wide variety of functional groups onto 
positions 1 and 3 of the imidazole ring. The target salts (1-
14) shown in Figure 1 have been obtained by quaternization 
of 1-substituted imidazole by variously substituted benzyl 
halides. The IMSs were obtained as solids, which have 
been observed to be air stable, except compound 9, and 
soluble in chlorinated solvents and alcohol. The salts 
could be purified by recrystallization from ethanol or 
CH2Cl2 (DCM) and by addition of Et2O. The IMSs were 
identified by NMR spectroscopy. 1H-NMR chemical 
shifts were consistent with the proposed structures; the 
resonances for NCHN protons were observed as a sharp 
singlet between δ 9.47 and 10.39 ppm. 13C-NMR of these 
salts showed the C2 carbon between δ 136.4 and 141.3 
ppm. The representative 1H- and 13C-NMR spectra of the 
compounds 1, 2, 3, 6, 11 were given as Supplementary 
Data (Figure 1-10).
FIGURE 1- Synthesis and formula of the imidazolium salts (1-14) used for antimicrobial activity.
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All of the compounds used in this study were 
tested for their in vitro antimicrobial activity by the agar 
well diffusion method. After then compounds showing 
antimicrobial activity were examined by MIC. Inhibition 
zones (mm) of the compounds were listed in Table I. 
In addition, the assay, were compared with knowing 
reference antibiotic and antifungal reagents. MIC values 
forming inhibition zone (mm) of the compounds were 
listed in Table II. 
Compounds 1, 2, 3 and 6 demonstrated stronger 
activity against M. luteus, ATCC 9341, S. aureus ATCC 
25923, S. epidermidis ATCC 12228, B. cereus ATCC 
11778, B. subtilis ATCC 6633 and C. tropicalis. The 
other compounds had effect as follows: compounds 1 
and 2; 18-20 mm against S. aureus ATCC 25923 and S. 
epidermidis ATCC 12228 (Figure 2a), compounds 1 and 
3; 14-18 mm against M. luteus ATCC 9341 (Figure 2b), 
compound 1; 15-18 mm against B. cereus ATCC 11778 
and B. subtilis ATCC 6633 (Figure 3a, 3b) compound 
6;15 mm against C. tropicalis. In addition, compounds 1, 
2 and 3 showed effects slightly against L. monocytogenes 
ATCC 19112, M. luteus, ATCC 9341 and S. aureus ATCC 
25923, respectively. 
However, 1, 2 and 11 showed the lowest effects 
against B. thrungiensis, B. cereus ATCC 11778 and S. 
epidermidis ATCC 12228, respectively. For example, 
compound 1, 2 and 11 had effect 10 mm B. thrungiensis, 
8 mm B. cereus ATCC 11778 and 9 mm S. epidermidis 
ATCC 12228, respectively On the other hand, 4, 5, 7, 8, 9, 
10, 12, 13 and 14 had no effect on the test microorganisms 
examined (Table I).
MIC values in Table II have also showed that 
some of the compounds tested presented noteworthy 
antimicrobial activity on the tested microorganisms. 
Compounds 1, 2 and 3 have revealed a strong activity 
against some bacterial cultures such as M. luteus ATCC 
9341 (compound 1 = 16 μg mL-1, 2 = 64 μg mL-1, 3 =32 μg 
mL-1), S. aureus ATCC 25923, (compound 1 = 8 μg mL-1, 
2 = 16 μg mL-1), S. epidermidis ATCC 12228 (compound 
1 = 8 μg mL-1, 2 = 16 μg mL-1, 3 = 32 μg mL-1), B. subtilis 
ATCC 6633 (1= 16 μg mL-1), B. cereus ATCC 11778 (1 = 
32 μg mL-1), L. monocytogenes ATCC 19112 (compound 
1 = 64 μg mL-1), C. tropicalis (compound 6 = 32 μg mL-1). 
However, compounds 1, 2, 3 and 11 have displayed lower 
effect against Bacillus thrungiensis (compound 1 = 128 μg 
mL-1, 2 = 256 μg mL-1), S. aureus ATCC 25923 (compound 
3 = 128 μg mL-1), S. epidermidis ATCC 12228 (compound 
11 = 256 μg mL-1). 
Micrococcus luteus does not regard as a pathogen 
bacteria but it can cause skin infections in individual 
with a decreased immune system such as new-born 
infants or patients with AIDS. The skin infections or 
chronic cutaneous infections result in pruritic eruptions 
of the skin in some areas as well as scattered papule 
lesions with or without central ulcerations (Smith et 
al., 1999). Recently, this organism was recognized as 
an opportunistic pathogen and has been implicated in 
recurrent bacteraemia, septic shock, septic arthritis, 
endocarditis, meningitis, intracranial suppuration, and 
cavitating pneumonia in immunosuppressed patients 
(Greenblatt et al., 2004).
Staphylococcus epidermidis generates biofilms to 
grow on plastic devices placed within the body (Costerton, 
Stewart, Greenberg, 2009). This happens most commonly 
on intravenous catheters and medical prostheses (Hedin, 
1993). Infection can also appear in dialysis patients or 
anyone with an implanted plastic device that may have 
been contaminated. It also causes endocarditis, most often 
in patients with defective heart valves. In some other cases, 
sepsis can occur in hospital patients. The spread of the 
infection has been shown reduced with the hand washing 
(Otto, 2009).
FIGURE 2 - a - Effects of compounds 1 (R1), 2 (R5), 3 (R8), 
11(R13) against Stapylococcus epidermidis ATCC 12228. b - 
Effects of compounds 1 (R1), 2 (R5), 3 (R8), 11(R13) against 
Micrococcus luteus ATCC 9341.
FIGURE 3- a - Effects of compounds 1 (R1), 2 (R5), 3 (R8), 
11(R13) against Bacillus cereus ATCC 11778. b - Effects of 
compounds 1 (R1), 2 (R5), 3 (R8), 11(R13) against Bacillus 
subtilis ATCC 6633.
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TABLE II - Antimicrobial activities of compounds as determined by MIC values (µg mL-1)
Test microorganisms 1 2 3 6 11 Str NS 100
Micrococcus luteus ATCC 9341 16 64 32 _ _ 32 NT
Stapylococcus aureus ATCC 25923 8 16 128 _ _ 32 NT
Stapylococcus epidermidis ATCC 12228 8 16 32 _ 256 64 NT
Bacilllus cereus ATCC 11778 16 _ _ _ _ 64 NT
Bacillus subtilis ATCC 6633 32 _ _ _ _ 64 NT
Bacillus thrungiensis* 128 256 _ _ _ 64 NT
Listeria monocytogenes ATCC 19112 64 _ _ _ _ 64 NT
Candida tropicalis* _ _ _ 32 _ NT 64
1: N-(2,4,6-trimethylphenyl)-N’-(2,4,6-trimethylbenzyl)imidazolium bromide, 2: N-(2,4,6-trimethylphenyl)-N’-(2,3,5,6-
tetramethylbenzyl)imidazolium bromide, 3: N-(2,4,6-trimethylphenyl)-N’-(2,3,4,5,6-pentamethylbenzyl)imidazolium bromide, 
6: N-(ferrocenylethyl)-N’-(2,4,6-trimethylphenyl)imidazolium chloride, 11: N-(butyl)-N’-(2,3,5,6-tetramethylbenzyl)imidazolium 
bromide. Compounds 4, 5, 7, 8, 9, 10, 12, 13 and 14 did not show antimicrobial activity. Str = Streptomycin, NS 100= Nystatine. 
(-): Not tested. * From the Faculty of Medicine, Adnan Menderes University.
TABLE I - Antimicrobial activities of unsymmetrically substituted imidazolium salts (1000 µg mL-1) (Inhibition zone mm)
Inhibition zone (mm)
Test Microorganisms
Compounds Reference antibiotics
1 2 3 6 11 C30 CN10 TE30 E15 AMP10 NS100
Escherichia coli ATCC 35218 _ _ _ _ _ 24 21 15 11 _ NT
Salmonella typhimurium ATCC 14028 _ _ _ _ _ 17 16 15 8 8 NT
Micrococcus luteus, ATCC 9341 18 12 14 _ _ 25 15 26 30 28 NT
Stapylococcus aureus ATCC 25923 20 19 11 _ _ 23 20 22 23 20 NT
Stapylococcus epidermidis ATCC 12228 20 18 14 _ 9 22 17 19 11 17 NT
Bacilllus cereus ATCC 11778 15 8 _ _ _ 23 24 25 26 _ NT
Bacillus subtilis ATCC 6633 18 12 _ _ _ 22 20 12 25 _ NT
Bacillus thrungiensis* 10 _ _ _ _ 26 21 15 28 _ NT
Entereococcus faecalis ATCC 29212 _ _ _ _ _ 16 11 19 _ 14 NT
Streptococcus pneumoniae ATCC 27336 _ _ _ _ _ 24 20 15 _ _ NT
Serratia marcescens ATCC 13880 _ _ _ _ _ 23 19 10 _ 15 NT
Proteus vulgaris ATCC 33420 _ _ _ _ _ 17 24 16 20 _ NT
Listeria monocytogenes ATCC 19112 13 _ _ _ _ 16 11 10 _ _ NT
Enterobacter aerogenes ATCC 13048 _ _ _ _ _ 19 20 14 _ _ NT
Candida albicans ATCC 10231 _ _ _ _ _ NT NT NT NT NT 22
Candida utilis ATCC 9950 _ _ _ _ _ NT NT NT NT NT 21
Candida tropicalis* _ _ _ 15 _ NT NT NT NT NT 15
Candida glabrata* _ _ _ _ _ NT NT NT NT NT 16
Saccharomyces cerevisiae ATCC 9763 _ _ _ _ _ NT NT NT NT NT 15
(-): Zone did not occur. NT: Not tested; Compounds 4, 5, 7, 8, 9, 10, 12, 13 and 14 showed no antimicrobial activity. *Special gift from the 
Faculty of Medicine, Adnan Menderes University. 1: N-(2,4,6-trimethylphenyl)-N’-(2,4,6-trimethylbenzyl)imidazolium bromide, 2: N-(2,4,6-
trimethylphenyl)-N’-(2,3,5,6-tetramethylbenzyl)imidazolium bromide, 3: N-(2,4,6-trimethylphenyl)-N’-(2,3,4,5,6-pentamethylbenzyl)
imidazolium bromide, 4: N-(2,4,6-trimethylphenyl)-N’-(hydroxyethyl)imidazolium bromide, 5: N-(2,4,6-trimethylphenyl)-N’-(ethylamine)
imidazolium chloride hydrochloride, 6: N-(ferrocenylethyl)-N’-(2,4,6-trimethylphenyl)imidazolium chloride, 7: N-(methyl)-N’-(2,3,5,6-
tetramethylbenzyl)imidazolium bromide, 8: N-(methyl)-N’-(2,3,4,5,6-pentamethylbenzyl)imidazolium bromide, 9: N-(methyl)-N’-(2-
methoxyethyl)imidazolium chloride, 10: N-(butyl)-N’-(2,4,6-trimethylbenzyl)imidazolium bromide, 11: N-(butyl)-N’-(2,3,5,6-tetramethylbenzyl)
imidazolium bromide, 12: N-(butyl)-N’-(2,3,4,5,6-pentamethylbenzyl)imidazolium bromide, 13: N-(1-methyl-2-oxopropyl)-N’-(2,3,5,6-
tetramethylbenzyl)imidazolium bromide, 14: N-(1-methyl-2-oxopropyl)-N’-(2,3,4,5,6-pentamethylbenzyl)imidazolium bromide. C30: 
Chloramphenicol (30 mg Oxoid); CN10: Gentamycin (10 mg, Oxoid); TE30: Tetracycline (30 mg, Oxoid); E15: Erytromycin (15 mg, Oxoid); 
AMP10: Ampicillin (10 mg, Oxoid); NS: Nystatine (100 mg, Oxoid). 
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Members of the genus Bacillus are aerobic spore 
forming rods which are ubiquitous in nature (Tuazon, 
2000). Despite their widespread distribution, even as a 
normal skin flora, Bacillus spp. rarely causes infections. 
The exception is Bacillus cereus, which is a well-
known cause of food poisoning and a dreaded cause of 
posttraumatic endophthalmitis (Tuazon, 2000). B. cereus 
can also cause opportunistic infections, mainly in the 
immunocompromised host (Tuazon, 2000; Drobniewski, 
1993). Besides, B. subtilis is only known as a cause of 
disease in severely immunocompromised patients and it 
rarely causes food poisoning. (Oggioni et al., 1998; Ryan, 
Ray, 2004). 
Listeria monocytogenes is the bacterium that 
causes the infection listeriosis. This bacterium results 
in septicemia, meningitis, encephalitis, corneal ulser, 
pneumonia (Armstrong, Fung, 1993).
Candida tropicalis has emerged as a potentially 
dangerous opportunistic fungus. This may be due to an 
increased awareness and specific identification of C. 
tropicalis as an etiologic agent of infection and an increase 
in the number of compromised patients susceptible to 
opportunistic fungi (Horn et al., 1985). C. tropicalis also 
causes variety of infections including pyelonephritis 
(Seidenfeld et al., 1982) lower urinary tract infections, 
thrombophlebitis, arthritis, bursitis, meningitis, multiple 
organ infection, pericarditis and candidia vulvovaginitis 
(Seidenfeld et al., 1982; Finberg et al., 2004). 
As a result, imidazolium salts containing ferrocene 
(compound 6) were determined to be inactive against 
microorganisms, ii) binding of the alkyl group instead of 
the aryl group (compounds 2 and 3), except 1 and 11, to 
one of the nitrogen atoms of the imidazole ring decreased 
the activity against microorganisms, iii) a decrease 
were identified in activity against microorganisms with 
increasing steric hindrance. 
CONCLUSION
In summary, we have investigated antimicrobial 
activity of some N-substituted imidazolium salts (1-
14). The compounds were characterized by NMR 
spectroscopy (1H- and 13C-NMR). Compounds 1 and 
2 were found that the methyl bearing benzyl group as 
substituent on imidazolium ring had the specific activity 
against Gram-positive bacteria. Remarkable activity was 
found in compound 2 carrying a methyl bearing benzyl 
substituent on the imidazolium ring. MICof the most 
active derivatives (1 and 2) were shown to be as low as 8 
µg/mL against S. aureus ATCC 25923 and S. epidermidis 
ATCC 12228, and 16 µg/mL against S. aureus ATCC 
25923 and S. epidermidis ATCC 12228. Only one of the 
compounds synthesized (6) was effective against yeast (C. 
trophicalis). It is worthy to mention that the introduction 
of the alkylated benzyl group to the nitrogen atom on the 
imidazolium ring increased MIC values.
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